Momelotinib before and after stem cell transplant for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of myelofibrosis (primary or secondary) that is considered intermediate-2, high-risk, or intermediate-1 with certain risk factors like needing blood transfusions or having a high-risk gene mutation.
- You are at least 18 years old.
- You are planning to have a stem cell transplant from a matched related or unrelated donor, using a reduced-intensity conditioning regimen and cells from your donor's blood.
- You are willing to switch your current JAK inhibitor treatment to momelotinib before the transplant if you are taking one.
- You do not have severe organ problems, active infections, or a history of a different cancer in the last 2 years.
- If you are a woman who could become pregnant, you must use highly effective birth control during the study and for 1 week after the last dose. Men with partners who could become pregnant must use condoms or have had a vasectomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
This trial tests whether a stem cell transplant from a half-matched (haploidentical) donor can help people with myelofibrosis. You might join if you don't have a fully matched sibling or unrelated donor.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.